After receiving accreditation from the Japanese Ministry of Health for its Patalganga facility, Elder Pharmaceuticals is planning to enter into the Japanese pharma market during the current fiscal.
The Japanese pharmaceutical market is valued at about $70 billion. The company’s planning to acquire about 1-2% of the market share.
The company is positioning itself to become a supplier of active pharmaceutical ingredients (APIs) and advanced intermediates to tap the vital Japanese market for the future growth of the company. The company’s plant at Patalganga manufactures APIs.
Elder Pharmaceuticals has also developed two products going off-patent in the Japanese market in 2014. One of the products is from the central nervous system (CNS) category and the second is from the gastrointestinal (GI) segment.
